PGR and breast cancer: Estrogen and progesterone receptors (ER and PR) and HER2 (ERBB2) are used as biomarkers to aid in the histopathological classification and management of BC subtypes, with hormone receptor and ERBB2 positive tumors benefiting from targeted therapies.